Search Results - "Ching, K.A."

699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers by Powles, T.B., Loriot, Y., Bellmunt, J., Sternberg, C.N., Sridhar, S., Petrylak, D.P., Tambaro, R., Dourthe, L.M., Alvarez-Fernandez, C., Aarts, M., Mu, X.J., Ching, K.A., Pu, J., Roychoudhury, S., Davis, C.B., di Pietro, A., Grivas, P.

Get full text

Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) by Albiges, L., Rini, B.I., Haanen, J B A G, Motzer, R.J., Kollmannsberger, C.K., Negrier, S., Nole, F., Bedke, J., Bilen, M.A., Nathan, P., Tomita, Y., Huang, B., Ching, K.A., Chudnovsky, A., Robbins, P.B., di Pietro, A., Thomaidou, D., Choueiri, T.K.

Get full text

910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S) by Choueiri, T.K., Larkin, J.M.G., Pal, S.K., Motzer, R.J., Venugopal, B., Alekseev, B.Y., Miyake, H., Gravis, G., Bilen, M.A., Chudnovsky, A., Ching, K.A., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

“…Despite advances in clear cell RCC treatment, pts with sRCC have poor prognosis and are more resistant to VEGF-targeted therapy. In JAVELIN Renal 101…”
Get full text

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) by Albiges, L., Rini, B.I., Haanen, J B A G, Motzer, R.J., Kollmannsberger, C.K., Negrier, S., Nole, F., Bedke, J., Bilen, M.A., Nathan, P., Tomita, Y., Huang, B., Ching, K.A., Chudnovsky, A., Robbins, P.B., di Pietro, A., Thomaidou, D., Choueiri, T.K.

“…On the basis of noninferiority outcomes for pts with metastatic disease who received S vs pts who underwent uCN followed by S (Mejean NEJM 2018), the role of…”
Get full text

Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S) by Choueiri, T.K., Larkin, J.M.G., Pal, S.K., Motzer, R.J., Venugopal, B., Alekseev, B.Y., Miyake, H., Gravis, G., Bilen, M.A., Chudnovsky, A., Ching, K.A., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

Get full text

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial by Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

“…Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the…”
Get full text

Large-Scale Analysis of the Human and Mouse Transcriptomes by Su, Andrew I., Cooke, Michael P., Ching, Keith A., Hakak, Yaron, Walker, John R., Wiltshire, Tim, Orth, Anthony P., Vega, Raquel G., Sapinoso, Lisa M., Moqrich, Aziz, Patapoutian, Ardem, Hampton, Garret M., Schultz, Peter G., Hogenesch, John B.

“…High-throughput gene expression profiling has become an important tool for investigating transcriptional activity in a variety of biological samples. To date,…”
Get full text

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: ESMO Open Volume 6, Issue 3, June 2021, 100101 by Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

Get full text

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ESMO Open Volume 6, Issue 3, June 2021, 100101] by Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.

Get full text